- Home
- ANAB
ANAB
AnaptysBio Inc.
as 12-27-2024 12:30pm EST
AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, our PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, our BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).
| Founded: | 2005 | Country: | United States |
| Employees: | N/A | City: | SAN DIEGO |
| Market Cap: | 759.5M | IPO Year: | 2017 |
| Target Price: | $42.67 | AVG Volume (30 days): | 777.9K |
| Analyst Decision: | Buy | Number of Analysts: | 11 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -6.04 | EPS Growth: | N/A |
| 52 Week Low/High: | $13.67 - $41.31 | Next Earning Date: | 11-05-2024 |
| Revenue: | $57,172,000 | Revenue Growth: | 282.17% |
| Revenue Growth (this year): | 233.68% | Revenue Growth (next year): | -37.51% |
Stock Insider Trading Activity of AnaptysBio Inc. (ANAB)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| RENTON HOLLINGS | ANAB | Director | Nov 29 '24 | Sell | $25.00 | 10,000 | $250,000.00 | 1,950 |
Latest AnaptysBio Inc. News
ANAB Breaking Stock News: Dive into ANAB Ticker-Specific Updates for Smart Investing
MT Newswires
9 days ago
Truist Securities Cuts Price Target on AnaptysBio to $20 From $30, Maintains Hold Rating
MT Newswires
14 days ago
UBS Adjusts AnaptysBio Price Target to $18 From $33, Maintains Neutral Rating
Zacks
15 days ago
AnaptysBio Stock Down as Eczema Study Fails to Meet Goals
Clinical Trials Arena
15 days ago
AnaptysBio’s atopic dermatitis trial of BTLA agonist misses endpoints
MT Newswires
16 days ago
Sector Update: Health Care Stocks Softer Late Afternoon
MT Newswires
16 days ago
Sector Update: Health Care
Benzinga
16 days ago
AnaptysBio Discontinues Investment In Eczema Candidate After Disappointing Data
MT Newswires
16 days ago
Top Midday Decliners
Compare ANAB vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "ANAB AnaptysBio Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.